Onur Atasoylu

Onur Atasoylu

Auto-generated profile, based on publicly available information

Onur Atasoylu

A Chemistry Research Laboratory , Department of Chemistry , University of Oxford , Oxford OX1 3TA , UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2017 in Chemical Science
Verified
Journal Article
Open access
PDF file
TYTzu-Lan Yeh
Tzu-Lan Yeh
TLThomas M. Leissing
Thomas M. Leissing
MAMartine I. Abboud
Martine I. Abboud
CTCyrille C. Thinnes
Cyrille C. Thinnes
OAOnur Atasoylu
Onur Atasoylu
CSChristopher J. Schofield
Christopher J. Schofield
Inhibition of the human 2-oxoglutarate (2OG) dependent hypoxia inducible factor (HIF) prolyl hydroxylases (human PHD1–3) causes upregulation of HIF, thus promoting erythropoiesis and is therefore of therapeutic interest. We describe cellular, biophysical, and biochemical studies comparing four PHD inhibitors currently in clinical trials for anaemia treatment, that describe their mechanisms of action, potency against isolated enzymes and in cells, and selectivities versus representatives of other human 2OG oxygenase subfamilies. The ‘clinical’ PHD inhibitors are potent inhibitors of PHD catalyzed hydroxylation of the HIF-α oxygen dependent degradation domains (ODDs), and selective against most, but not all, representatives of other human 2OG dependent dioxygenase subfamilies. Crystallographic and NMR studies provide insights into the different active site binding modes of the inhibitors. Cell-based results reveal the inhibitors have similar effects on the upregulation of HIF target genes, but differ in the kinetics of their effects and in extent of inhibition of hydroxylation of the N- and C-terminal ODDs; the latter differences correlate with the biophysical observations.

16 July 2011 in Journal of the American Chemical Society
Verified
Journal Article
Open access
AIAmos B Smith III
Amos B Smith III
CRChristina A. Risatti
Christina A. Risatti
OAOnur Atasoylu
Onur Atasoylu
CBClay Bennett
Clay Bennett
JLJunke Liu
Junke Liu
QXQunli Xu
Qunli Xu
The design, synthesis, and biological evaluation of two diminutive forms of (+)-spongistatin 1, in conjunction with the development of a potentially general design strategy to simplify highly flexible macrocyclic molecules while maintaining biological activity, have been achieved. Examination of the solution conformations of (+)-spongistatin 1 revealed a common conformational preference along the western perimeter comprising the ABEF rings. Exploiting the hypothesis that the small-molecule recognition/binding domains are likely to comprise the conformationally less mobile portions of a ligand led to the design of analogues, incorporating tethers (blue) in place of the CD and the ABCD components of the (+)-spongistatin 1 macrolide, such that the conformation of the retained (+)-spongistatin 1 skeleton would mimic the assigned solution conformations of the natural product. The observed nanomolar cytotoxicity and microtubule destabilizing activity of the ABEF analogue provide support for both the assigned solution conformation of (+)-spongistatin 1 and the validity of the design strategy.